Global cancer burden attributable to tobacco smoking in 2022: a differential analysis by smoking status, sex, and development level
International Journal of Epidemiology · 14.10.2026 · 55 (6)
DOI: 10.1093/ije/dyag239 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Epidemiology, online erschienen am 06.11.2026. Verfasst von Veer Shah und 6 weiteren Autor:innen. Beteiligte Einrichtung: Icahn School of Medicine at Mount Sinai, New York, NY, United States. Hauptthemen laut MEDLINE: Neoplasms, Tobacco Smoking. Die Arbeit nennt 49 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Tobacco smoking is a leading preventable cause of cancer. We estimated its attributable cancer burden by smoking status (current vs. former), further stratified by cancer type, sex, country, and Human Development Index (HDI).
Methods
The Population Attributable Fraction (PAF) for cancer incidence and mortality due to tobacco were estimated across 175 countries by using 2000 Global Burden of Disease smoking prevalence and 2022 Global Cancer Observatory cancer data. Relative risks (RRs) were derived from large pooled and meta-analyses, and population data from the World Bank. Countries were categorized by HDI.
Results
The global tobacco PAF was 17.2% for cancer incidence and 22.4% for mortality. Lung cancer had the highest RR for current smokers (8.96) and laryngeal cancer for former smokers (4.65). Males had a higher cancer incidence (26.1%) and mortality (32.1%) burden than females (8.0% and 10.2%, respectively). Cancers with the highest smoking PAF were laryngeal (70.1%), lung (66.9%), pharyngeal (63.5%), oral cavity (38.5%), and bladder (39.4%). PAF estimates for incidence were 5.4% in low-HDI (49 countries), 15.0% in medium-HDI [41], 19.3% in high-HDI [32], and 17.4% in very-high-HDI [32] countries; corresponding mortality estimates were 6.4% (low-HDI), 17.4% (medium-HDI), 26.0% (high-HDI), and 23.6% (very-high-HDI), respectively.
Conclusion
Approximately one in six cancer cases and one in four cancer deaths globally are attributable to tobacco smoking. Despite declining smoking prevalence, former smokers account for a substantial burden long after cessation. Males and higher-HDI countries bear a greater burden.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Icahn School of Medicine at Mount Sinai, New York, NY, United States.
- Renaissance School of Medicine at Stony, Brook University, Stony Brook, NY, United States.
- Stony Brook Cancer Center, Stony Brook University, Stony Brook, NY, United States.
- The Johns Hopkins University School of Medicine, Baltimore, MD, United States.
- Division of General Surgery, Department of Surgery, Icahn School of Medicine at Mount Sinai, New York, NY, United States.
- Department of Medical and Surgical Sciences, University of Bologna, Bologna, Italy.
ORCID-Profile: Darshi Shah, Paolo Boffetta
Zitieren
APA
Shah, V., Shah, D., Shah, K., Wu, J., Bruno, D., Boffetta, P., & Seyyedsalehi, M. S. (2026). Global cancer burden attributable to tobacco smoking in 2022: a differential analysis by smoking status, sex, and development level. International Journal of Epidemiology, 55(6). https://doi.org/10.1093/ije/dyag239
Vancouver
Shah V, Shah D, Shah K, Wu J, Bruno D, Boffetta P, et al. Global cancer burden attributable to tobacco smoking in 2022: a differential analysis by smoking status, sex, and development level. International Journal of Epidemiology. 2026;55(6). doi:10.1093/ije/dyag239
BibTeX
@article{Shah2026,
author = {Shah, Veer and Shah, Darshi and Shah, Karan and Wu, Jeanne and Bruno, Daniele and Boffetta, Paolo and Seyyedsalehi, Monireh Sadat},
title = {Global cancer burden attributable to tobacco smoking in 2022: a differential analysis by smoking status, sex, and development level},
journal = {International Journal of Epidemiology},
year = {2026},
volume = {55},
number = {6},
doi = {10.1093/ije/dyag239}
}
EUVIMED